The STAT2 Knockout A549 Cell Line is a CRISPR/Cas9-edited knockout cell line derived from the widely used A549 lung adenocarcinoma epithelial cell line. This product provides a genetically defined loss-of-function model for functional studies of STAT2, a key signal transducer and activator of transcription that mediates type I interferon (IFN) responses. The knockout has been achieved through CRISPR/Cas9-mediated gene disruption, resulting in the ablation of STAT2 protein expression. This cell line serves as a critical tool for systematically dissecting JAK-STAT pathway mechanisms, antiviral innate immunity, and the broader network of interferon-dependent processes.
A549 cells were originally isolated from the lung adenocarcinoma of a 58-year-old male. They are extensively utilized as a model for human alveolar type II epithelial cells and retain many characteristics of lung adenocarcinoma. Their robust growth, epithelial morphology, and stable phenotype make them suitable for a wide range of respiratory biology and cancer research applications. Importantly, A549 cells are highly responsive to type I interferons and are susceptible to infection by various respiratory viruses, rendering them an ideal host background for investigating signaling pathways involved in inflammation, immune surveillance, and antiviral defense in the pulmonary context.
STAT2 functions as a central transcription factor in the canonical type I IFN signaling cascade. Upon binding of IFN-alpha or IFN-beta to the heterodimeric receptor complex IFNAR1/IFNAR2, the associated tyrosine kinases TYK2 and JAK1 phosphorylate STAT2. This phosphorylation triggers heterodimerization with STAT1 and subsequent recruitment of IRF9 to form the interferon-stimulated gene factor 3 (ISGF3) complex. The ISGF3 complex translocates to the nucleus, where it binds to interferon-stimulated response elements (ISREs) and transcriptionally activates a broad array of interferon-stimulated genes (ISGs), including MX1, OAS1, and IFIT1, which encode antiviral effector proteins. Thus, STAT2 is an indispensable mediator of the entire type I IFN-induced transcriptional program. In this knockout cell line, disruption of STAT2 impairs ISGF3 formation and downstream ISG expression, providing a clean and defined background for pathway interrogation.
In the context of A549 lung adenocarcinoma cells, STAT2 knockout is particularly relevant for examining tumor-intrinsic interferon signaling and its interplay with immune evasion or immune surveillance mechanisms. A549 cells serve as a workhorse model for respiratory viral infections, including influenza A and SARS-CoV-2, where STAT2-dependent interferon responses are vital for controlling viral replication. This knockout model enables precise dissection of how lung epithelial cells orchestrate antiviral defenses and how oncogenic pathways might perturb these responses. Furthermore, it facilitates exploration of JAK-STAT signaling cross-talk in transformed epithelial cells, potentially uncovering therapeutic vulnerabilities or resistance mechanisms relevant to lung cancer.
This STAT2 knockout cell line is suitable for a diverse set of experimental applications, including interferon stimulation assays to monitor ISG induction kinetics, western blotting and immunofluorescence for STAT2 and phospho-STAT2 detection, co-immunoprecipitation to assess STAT1/STAT2/IRF9 complex assembly, and RT-qPCR profiling of antiviral ISGs such as MX1 and IFIT1. It can be employed in viral infection models to evaluate the role of STAT2 in host defense, in ISRE-luciferase reporter assays to quantify pathway activity, and in drug screening campaigns for modulators of interferon signaling. Additionally, it serves as a valuable tool for cancer immune surveillance studies and for analyzing the impact of STAT2 loss on tumor cell proliferation and apoptosis. For additional technical details, please contact Ascent Research.
